ProLectin-I / Bioxytran - LARVOL DELTA

Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug (GlobeNewswire) - "BIOXYTRAN...announced today that Nature Reviews Drug Discovery journal published a peer-reviewed article that supports the rationale behind the development of ProLectin-I for fibrosis and ProLectin-M as an antiviral drug....The review article independently supports Bioxytran’s drug development program for fibrosis and antiviral disease treatment."

Clinical • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease

Bioxytran Receives Approval to Initiate Trials with ProLectin-I (GlobeNewswire) - "BIOXYTRAN...announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ProLectin-I injection. The objective of this trial is to provide guidance for our future Phase II trial in Long COVID and Idiopathic Pulmonary Fibrosis (IPF). This is a separate and additional approval from the authorization that ProLectin-M received on December 2, 2022."

New P2 trial • Idiopathic Pulmonary Fibrosis